Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

[Current status and optimization strategies for diagnosis and treatment of neonatal culture-negative sepsis].

Created on 20 Nov 2026

Authors

Liang-Yu Chen, Qi Zhou

Published in

Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics. Volume 28. Issue 11. Pages 1413-1419. Nov 15, 2026.

Abstract

Overall, the diagnosis and treatment of neonatal sepsis have continued to improve; however, the clinical management of neonatal culture-negative sepsis (NCNS) has lagged relatively behind and is often characterized by overdiagnosis and inconsistent antibiotic regimens. These issues result in unnecessary antibiotic exposure, adversely affect the prognosis of the neonates, and exacerbate the burden of nosocomial antimicrobial resistance. Technologies such as pathogen detection, molecular biology-based techniques, and artificial intelligence are being continuously translated into practice, providing new methods for precision diagnosis. When effective differential triage of neonates with NCNS cannot be achieved, individualized risk stratification and hospital-wide quality improvement in antibiotic use are complementary and can support clinical decision-making. This review summarizes the definition, current status of diagnosis and treatment, and optimization strategies of NCNS, and provides a reference for the precision diagnosis and treatment of NCNS.

PMID:
43059343
Bibliographic data and abstract were imported from PubMed on 20 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 1
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement